Released September 09, 2021 | BEIJING
en
Researched by Industrial Info Resources (Sugar Land, Texas)--China's Tier 2 pharmaceutical contract development and manufacturing companies (CDMOs) have the opportunity to leap to Tier 1 status as more Pharmaceutical & Biotech companies in the West outsource their services, and as China sees the benefits of its Marketing Authorization Holder (MAH) pharmaceutical regulatory system. Tier 2 CDMOs have annual revenue of up to US$500 million, while Tier 1 CDMOs have revenue of more than US$500 million.
Chinese Tier 2 company Zhejiang Jiuzhou Pharmaceutical Company Limited (Taizhou, Zhejiang) says its CDMO business brought in US$158 million in revenue during the first half of fiscal year 2021, while its specialized active pharmaceutical ingredient (API) and intermediates business achieved US$101 million in revenue.
China implemented its MAH system in 2019 in a drive to more strongly regulate the industry.
Tier 1 companies in the global CDMO market include Lonza Group AG (Basel, Switzerland), Wuxi AppTec (Shanghai, China) (including Wuxi Biologics and Wuxi STA), Catalent Incorporated (NYSE:CTLT) (Somerset, New Jersey), Patheon N.V. (Waltham, Massachusetts), Aenova Group (Starnberg, Germany), Boehringer Ingelheim (BI) (Ingelheim, Germany), Siegfreid Holding AG (Zofingen, Switzerland), Samsung Biologics Company (Incheon, South Korea), Recipharm AB (Stockholm, Sweden), Albany Molecular Research Incorporated (AMRI) (Albany, New York) and Celltrion (Incheon). These vendors have employed various strategies to expand their product and application offerings and global footprint, and to augment their market shares.
Industrial Info is tracking seven CDMO projects in China, with a combined value of US$860.45 million. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for detailed reports.
Click on the image at right for an heat map showing CDMO project activity in China, from Industrial Info's Geolocator tool.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.
Chinese Tier 2 company Zhejiang Jiuzhou Pharmaceutical Company Limited (Taizhou, Zhejiang) says its CDMO business brought in US$158 million in revenue during the first half of fiscal year 2021, while its specialized active pharmaceutical ingredient (API) and intermediates business achieved US$101 million in revenue.
China implemented its MAH system in 2019 in a drive to more strongly regulate the industry.
Tier 1 companies in the global CDMO market include Lonza Group AG (Basel, Switzerland), Wuxi AppTec (Shanghai, China) (including Wuxi Biologics and Wuxi STA), Catalent Incorporated (NYSE:CTLT) (Somerset, New Jersey), Patheon N.V. (Waltham, Massachusetts), Aenova Group (Starnberg, Germany), Boehringer Ingelheim (BI) (Ingelheim, Germany), Siegfreid Holding AG (Zofingen, Switzerland), Samsung Biologics Company (Incheon, South Korea), Recipharm AB (Stockholm, Sweden), Albany Molecular Research Incorporated (AMRI) (Albany, New York) and Celltrion (Incheon). These vendors have employed various strategies to expand their product and application offerings and global footprint, and to augment their market shares.
Industrial Info is tracking seven CDMO projects in China, with a combined value of US$860.45 million. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for detailed reports.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.
